BHCM
KYMR icon

Brevan Howard Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Brevan Howard Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,107
Closed -$485K – 2138
2025
Q2 		$485K Buy
+11,107
New +$382K ﹤0.01% 1368
2024
Q1 		– Sell
-14,208
Closed -$362K – 1182
2023
Q4 		$362K Buy
+14,208
New +$254K ﹤0.01% 635

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Brevan Howard Capital Management's KYMR Position: Q3 2025 in Review

Brevan Howard Capital Management sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 11,107 shares — an estimated $485K sold.

Brevan Howard Capital Management first reported a position in KYMR in Q4 2023 and held it in 2 quarters. The position peaked at $485K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Brevan Howard Capital Management reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 11,107 Kymera Therapeutics shares in Q3 2025, an estimated $485K.
  • Brevan Howard Capital Management first reported a position in Kymera Therapeutics in Q4 2023 and held it in 2 quarters.
  • Brevan Howard Capital Management's Kymera Therapeutics position peaked at $485K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Brevan Howard Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.